YM 53705Alternative Names: Solifenacin hydrochloride; Solifenacin monohydrochloride; YM-53705
Latest Information Update: 26 May 1998
At a glance
- Originator Yamanouchi
- Class Urologics
- Mechanism of Action Muscarinic M3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Urinary incontinence
Most Recent Events
- 26 May 1998 Discontinued - Preclinical for Urinary incontinence in Japan (unspecified route)
- 16 May 1997 Preclinical development for Urinary incontinence in Japan (Unknown route)